Literature DB >> 14656482

Inhibition of steroidogenesis in Leydig cells by Müllerian-inhibiting substance.

Eric Fynn-Thompson1, Henry Cheng, Jose Teixeira.   

Abstract

Müllerian-inhibiting substance (MIS), a member of the transforming growth factor-beta family of cytokines that signal through a heteromeric complex of single-transmembrane serine/threonine kinase receptors, is required for Müllerian duct regression and normal reproductive tract development in the male embryo. However, the continued expression of MIS at high levels in males until puberty and its induction in females after birth suggested other roles for MIS. Additionally, Leydig cell development and steroidogenic capacity and ovarian follicle recruitment were abnormal in MIS-knockout or MIS-overexpressing mice. We have shown that MIS inhibits the cAMP-induced expression of cytochrome P450 C17alpha-hydroxylase/C17-20 lyase (Cyp17) mRNA both in vitro and in vivo. Our current efforts are to understand the molecular mechanisms regulating both MIS type II receptor (MISRII) expression and its signaling in rodent Leydig cell lines. MISRII expression in R2C cells requires both steroidogenic factor-1 and an unknown protein to bind to its proximal promoter in the context of 1.6 kb 5'-flanking DNA. When bound by MIS, signaling by the receptor in MA-10 cells blocks the protein kinase A-mediated induction of Cyp17 expression by a cAMP regulatory element-binding protein independent mechanism. We continue to investigate the molecular mechanisms of MISRII expression and possible interactions between MIS-regulated SMAD activation and cAMP signaling. These studies will provide a better understanding of the role played by MIS during postnatal life.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656482     DOI: 10.1016/j.mce.2003.09.015

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  7 in total

Review 1.  Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease.

Authors:  Bernard P Schimmer; Perrin C White
Journal:  Mol Endocrinol       Date:  2010-03-04

2.  Functional Genetic Variation in the Anti-Müllerian Hormone Pathway in Women With Polycystic Ovary Syndrome.

Authors:  Lidija K Gorsic; Matthew Dapas; Richard S Legro; M Geoffrey Hayes; Margrit Urbanek
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

3.  Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian-inhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells.

Authors:  Peter J Malloy; Lihong Peng; Jining Wang; David Feldman
Journal:  Endocrinology       Date:  2008-12-04       Impact factor: 4.736

4.  Screening and familial characterization of copy-number variations in NR5A1 in 46,XY disorders of sex development and premature ovarian failure.

Authors:  Steven M Harrison; Ian M Campbell; Melise Keays; Candace F Granberg; Carlos Villanueva; Grace Tannin; Andrew R Zinn; Diego H Castrillon; Chad A Shaw; Pawel Stankiewicz; Linda A Baker
Journal:  Am J Med Genet A       Date:  2013-08-05       Impact factor: 2.802

5.  Anti-Müllerian hormone recruits BMPR-IA in immature granulosa cells.

Authors:  Lauriane Sèdes; Arnaud Leclerc; Hadia Moindjie; Richard L Cate; Jean-Yves Picard; Nathalie di Clemente; Soazik P Jamin
Journal:  PLoS One       Date:  2013-11-28       Impact factor: 3.240

6.  The Nuclear Receptor COUP-TFII Regulates Amhr2 Gene Transcription via a GC-Rich Promoter Element in Mouse Leydig Cells.

Authors:  Samir Mehanovic; Raifish E Mendoza-Villarroel; Robert S Viger; Jacques J Tremblay
Journal:  J Endocr Soc       Date:  2019-10-01

Review 7.  Polycystic Ovarian Syndrome: A Complex Disease with a Genetics Approach.

Authors:  Himani Nautiyal; Syed Sarim Imam; Sultan Alshehri; Mohammed M Ghoneim; Muhammad Afzal; Sami I Alzarea; Emine Güven; Fahad A Al-Abbasi; Imran Kazmi
Journal:  Biomedicines       Date:  2022-02-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.